Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ILMN
+0.18 (0.14%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 126.91 - 128.56
52 week 126.39 - 196.47
Open 127.99
Vol / Avg. 0.00/1.47M
Mkt cap 18.81B
P/E 42.76
Div/yield     -
EPS 2.99
Shares 146.90M
Beta 1.17
Inst. own 95%
Jan 31, 2017
Q4 2016 Illumina Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 7, 2016
Illumina Inc at Citi Global Healthcare Conference - 8:45AM EST - Add to calendar
Nov 1, 2016
Q3 2016 Illumina Inc Earnings Call - Webcast
Nov 1, 2016
Q3 2016 Illumina Inc Earnings Release
Oct 10, 2016
Preliminary Q3 2016 Illumina Inc Earnings Call - Webcast
Oct 10, 2016
Preliminary Q3 2016 Illumina Inc Earnings Release
Sep 13, 2016
Illumina Inc at Morgan Stanley Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '16) 2016
Net profit margin 19.26% 20.61%
Operating margin 26.47% 27.61%
EBITD margin - 33.41%
Return on average assets 11.42% 13.02%
Return on average equity 24.07% 27.88%
Employees 4,600 -
CDP Score - -


5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.

Officers and directors

Jay T. Flatley Executive Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Francis A. deSouza President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Marc A. Stapley Chief Financial Officer, Executive Vice President, Chief Administrative Officer
Age: 46
Bio & Compensation  - Reuters
Christian O. Henry Chief Commercial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Tristan B. Orpin Executive Vice President - Clinical Genomics
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Omead Ostadan Executive Vice President - Operations, Products and Strategy
Age: 44
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Paula Dowdy Senior Vice President and General Manager
Bio & Compensation  - Reuters
Paul L. Bianchi Senior Vice President - Human Resources
Age: 54
Bio & Compensation  - Reuters